ERBB2 and breast carcinoma: Trastuzumab, a monoclonal antibody inhibiting HER2 activation by binding to the extracellular domain IV of HER2, improves clinical outcomes over HER2-amplified localized and advanced breast cancer, both as a single agent and in combination with chemotherapy.